These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27761932)

  • 1. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
    Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
    Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
    Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
    Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
    Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
    Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
    Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
    Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
    Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.
    Reeves SL; Dombkowski KJ; Peng HK; Phan H; Kolenic G; Creary SE; Madden B; Lisabeth LD
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30332. PubMed ID: 37046404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
    J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
    Azmet FR; Al-Kasim F; Alashram WM; Siddique K
    Saudi Med J; 2020 Jan; 41(1):46-52. PubMed ID: 31915794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.